Opitor-0
Based on 1 Customer Validation
Opitor-0 is a OPA1 GTPase inhibitor with an IC50 of 3.0 μM. Opitor-0 disrupts mitochondrial cristae structure and respiratory efficiency, induces mitochondrial fragmentation, enhances cBID-mediated cytochrome c release, and restores the sensitivity of triple-negative breast cancer (TNBC) cells to ABT-737 (HY-50907). Opitor-0 selectively reduces the migration and proliferation capacities of metastatic breast cancer cells, and induces cell death and apoptosis. Opitor-0 can be used in studies related to metastatic breast cancer and triple-negative breast cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 98.02%
- Formel: C30H25N5O2S
- Molecular Weight:519.62
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biologische Aktivität
Beschreibung
In Vitro
Opitor-0 (50 μM; 6-24 h) induces mitochondrial fragmentation in MCF10A, MCF10AT1 and MCF10CA1h breast cells; it selectively reduces mitochondrial respiratory efficiency and ATP-coupled respiration in metastatic MCF10CA1h and MCF10CA1a breast cancer cells[1].
Opitor-0 (1-50 μM; 5 h) induces concentration-dependent mitochondrial fragmentation in mtYFP-expressing MEF cells and HeLa cells[2].
Opitor-0 (50 μM; 20 h) selectively impairs the migratory capacity of metastatic MCF10CA1h and MCF10CA1a breast cancer cells, without affecting non-metastatic MCF10A and MCF10AT1 breast cancer cells[1].
Opitor-0 (50 μM; 24 h) selectively reduces the proliferative capacity of highly metastatic MCF10CA1a breast cancer cells, without affecting non-metastatic MCF10A, MCF10AT1 or moderately metastatic MCF10CA1h breast cancer cells[1].
Opitor-0 (50 μM) does not induce cell death in any tested breast cancer cell lines after 24 h of treatment, but causes a small yet significant increase in the level of cell death in metastatic MCF10CA1h and MCF10CA1a breast cancer cells after 72 h of treatment, without affecting non-metastatic MCF10A and MCF10AT1 breast cancer cells[1].
Opitor-0 potently inhibits the GTPase activity of wild-type mini-rOpa1, with an IC50 of 3.0 μM[2].
Opitor-0 (25-125 μM; 30 min) potently enhances cBID-mediated cytochrome c release from purified mouse liver mitochondria[2].
Opitor-0 (5-100 μM; administered for 5 h after 12 h of preincubation with 10-20 μM ABT-737) exerts a strong synergistic effect with the Bcl-2 inhibitor ABT-737 (HY-50907) to induce caspase-dependent apoptosis in MDA-MB-231 triple-negative breast cancer cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MCF10A, MCF10AT1, MCF10CA1h, MCF10CA1a
-
Concentration:50 μM
-
Incubation Time:20 h
-
Result:Significantly reduced wound closure (increased remaining gap area) in metastatic MCF10CA1h and MCF10CA1a cells over 20 h.
Showed no significant effect on non-metastatic MCF10A and MCF10AT1 cells.
-
Cell Line:MCF10A, MCF10AT1, MCF10CA1h, MCF10CA1a
-
Concentration:50 μM
-
Incubation Time:24 h
-
Result:Significantly reduced the percentage of Phospho-Histone H3-positive nuclei in highly metastatic MCF10CA1a cells cultured in both Plasmax and DMEM.
Showed no significant effect on MCF10A, MCF10AT1, or MCF10CA1h cells.
-
Cell Line:MCF10A, MCF10AT1, MCF10CA1h, MCF10CA1a
-
Concentration:50 μM
-
Incubation Time:24 h; 72 h
-
Result:Did not induce significant cell death in any of the tested cell lines after 24 h treatment.
Induced a small but significant increase in Annexin V/PI-positive cells in metastatic MCF10CA1h and MCF10CA1a cells after 72 h treatment.
Showed no significant effect on non-metastatic MCF10A and MCF10AT1 cells after 72 h treatment.
Chemical Information
-
Appearance Solid
-
Molecular Weight 519.62
-
Formel C30H25N5O2S
-
Color Off-white to yellow
-
SMILES
CC1=NN(C2=CC=CC=C2)C3=C1C=C(C(NC(C(N(N4CC5=CC=CC=C5)C6=CC=CC=C6)=O)=C4C)=O)S3
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 35 mg/mL (67.36 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Protokoll
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Reinheit & Dokumentation
-
Data Sheet (282 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9245 mL | 9.6224 mL | 19.2448 mL | 48.1121 mL |
| 5 mM | 0.3849 mL | 1.9245 mL | 3.8490 mL | 9.6224 mL | |
| 10 mM | 0.1924 mL | 0.9622 mL | 1.9245 mL | 4.8112 mL | |
| 15 mM | 0.1283 mL | 0.6415 mL | 1.2830 mL | 3.2075 mL | |
| 20 mM | 0.0962 mL | 0.4811 mL | 0.9622 mL | 2.4056 mL | |
| 25 mM | 0.0770 mL | 0.3849 mL | 0.7698 mL | 1.9245 mL | |
| 30 mM | 0.0641 mL | 0.3207 mL | 0.6415 mL | 1.6037 mL | |
| 40 mM | 0.0481 mL | 0.2406 mL | 0.4811 mL | 1.2028 mL | |
| 50 mM | 0.0385 mL | 0.1924 mL | 0.3849 mL | 0.9622 mL | |
| 60 mM | 0.0321 mL | 0.1604 mL | 0.3207 mL | 0.8019 mL |